20Med Therapeutics
Bioresponsive polymeric nanoparticles for the delivery of RNA and DNA based vaccines and therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
N/A | Grant | ||
| Total Funding | 000k | ||
Related Content
20Med Therapeutics is a Dutch biotechnology company specializing in the development of prophylactic and therapeutic vaccines. Utilizing proprietary bioresponsive polymer nanoparticle technology, the company is creating a non-viral delivery platform aimed at the swift development of RNA and DNA-based vaccines. This technology is particularly applicable in combating infectious diseases and cancer. The manufacturing process for these polymeric nanoparticles is straightforward, scalable, and independent of the payload, which allows for rapid development and deployment.
The company primarily serves the healthcare and pharmaceutical sectors, focusing on clients who require advanced vaccine solutions. Operating within the biotechnology market, 20Med Therapeutics employs a business model centered around research and development, partnering with healthcare providers, and licensing its technology to pharmaceutical companies. Revenue is generated through these partnerships, licensing agreements, and potentially through direct sales of their vaccine solutions.
Keywords: nanotechnology, RNA therapeutics, DNA vaccines, non-viral delivery, infectious diseases, cancer, biotechnology, scalable manufacturing, healthcare, pharmaceutical.